RPCEC00000150
Completed
未知
Immunogenicity of a pneumococcal conjugate vaccine and impact on carriage in Venezuelan children at risk of invasive pneumococcal infection
Servicio Autónomo Instituto de Biomedicina0 sites110 target enrollmentMarch 6, 2013
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Infection Prophylaxis of Streptococcus pneumoniae
- Sponsor
- Servicio Autónomo Instituto de Biomedicina
- Enrollment
- 110
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The study included male and female subjects aged 2 to 60 months of age with at least one of the following immunosuppressive conditions that define as a child at high risk for pneumococcal invasive disease: HIV infection Sickle cell disease Asplenia Congenital immunodeficiency Chronic heart disease Chronic pulmonary disease Cerebrospinal fluid leak Chronic renal failure Patients with immunosuppressive therapy (Neoplasms, leukemia, etc) Diabetes mellitus
Exclusion Criteria
- •Exclusion criteria for this study included; acute disease at enrollment and antibiotic treatment in the last 7 days
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Immunogenicity of conjugate pneumococcal vaccine (Prevenar) in patients with ataxia -telangiectasia (AT) including a randomised study of one versus two doses of vaccine. - Immunogenicity of Prevenar in Ataxia telangiectasiaEUCTR2005-004122-70-GBGreat Ormond Street Hospital30
Active, not recruiting
Not Applicable
Immune response to pneumococcal conjugate vaccine in adults receiving hepatitis A vaccine concomitantly18 years old or older volunteers with general good healthEUCTR2012-003484-22-FIHelsinki University Central Hospital600
Active, not recruiting
Not Applicable
Immune response to pneumococcal conjugate vaccine in adults receiving hepatitis A vaccine concomitantlyEUCTR2012-003484-22-SEHelsinki University Central Hospital300
Active, not recruiting
Phase 1
Immune response test as new predictor for successful TKI stop in patients with chronic myeloid leukemiaChronic myeloid leukemiaMedDRA version: 21.0Level: LLTClassification code 10009016Term: Chronic myeloid leukemia in remissionSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10009015Term: Chronic myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2020-002850-26-NLAlbert Schweitzer Hospital57
Recruiting
Not Applicable
Vaccination response to pneumococcal antigen as novel predictor for successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia.NL-OMON55091Albert Schweitzer Ziekenhuis57